Exciting breakthroughs in rare disease treatments mean more patients are gaining access to cutting-edge therapies - and specialty pharmacies are playing a crucial role in delivering these medications with expert support. But what exactly do they do, and when do they come into play?
AllMyHealth’s latest guide breaks it all down - exploring how specialty pharmacies work, their expanding role in patient care, and how individuals can engage with them. Plus, we spotlight specialty pharmacies such as Orsini, Accredo & PANTHERx which support PBC treatment.
Available in both text and audio formats - dive in today and share with your community!
The review by Martins & Levy (2025) delves into the concept of "deep response" to ursodeoxycholic acid (UDCA) treatment in primary biliary cholangitis (PBC). Deep response is characterized by the normalization of specific biochemical markers, such as alkaline phosphatase and bilirubin. These markers are important because they can indicate how well the liver is functioning.
The review suggests that achieving a deep response could be a more effective goal for managing PBC, as it may be linked to better long-term outcomes for patients. Martins & Levy argue for considering deep response as a new clinical standard, which could influence health policies and guide clinicians in making more informed decisions about patient care. The review underscores the importance of re-evaluating treatment goals in light of emerging evidence to improve the management of PBC.
